SLC6A2 — Norepinephrine Transporter
Introduction
Mermaid diagram (expand to render)
SLC6A2 (Solute Carrier Family 6 Member 2), also known as the norepinephrine transporter (NET), is a gene encoding a critical membrane transport protein responsible for the reuptake of norepinephrine (noradrenaline) from the synaptic cleft back into presynaptic neurons. This function is essential for terminating noradrenergic signaling, regulating the temporal and spatial dynamics of neurotransmission, and maintaining neurotransmitter homeostasis in the central and peripheral nervous systems. NET is a member of the Na+/Cl- dependent neurotransmitter transporter family (SLC6A), which also includes transporters for dopamine (DAT, SLC6A3), serotonin (SERT, SLC6A4), and GABA (GATs)[@byerly1989][@pacholczyk1991].
The SLC6A2 gene is located on chromosome 16q12.2 and encodes a protein of 617 amino acids with an estimated molecular weight of approximately 70 kDa. The protein adopts a 12-transmembrane domain topology characteristic of the SLC6 transporter family, with intracellular N- and C-termini and an extracellular loop containing glycosylation sites. NET functions as a symporter that couples the uptake of norepinephrine to the inward flow of Na+ and Cl- ions down their electrochemical gradients, with a reported Km for norepinephrine of approximately 0.1-0.5 muM["@gu2006"][@kaufmann2006].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Norepinephrine Transporter</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SLC6A2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Solute Carrier Family 6 Member 2</td></tr>
<tr><td><strong>Protein Name</strong></td><td>Norepinephrine Transporter (NET)</td></tr>
<tr><td><strong>Chromosome</strong></td><td>16q12.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[6530](https://www.ncbi.nlm.nih.gov/gene/6530)</td></tr>
<tr><td><strong>OMIM</strong></td><td>163910</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000170270</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P23975](https://www.uniprot.org/uniprot/P23975)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), [Depression](/diseases/depression), [ADHD](/diseases/adhd), [Orthostatic Intolerance](/diseases/orthostatic-intolerance)</td></tr>
</table>
</div>
Molecular Function
Transport Mechanism
NET operates through a sodium-dependent secondary active transport mechanism:
Ion coupling: Transport of one norepinephrine molecule is coupled to the influx of one Na+ and one Cl- ion
Conformational change: Binding of substrates and ions induces a conformational transition from outward-open to inward-open states
Release: Substrate and ions are released into the cytoplasm
Recycling: The transporter returns to the outward-open conformationThe stoichiometry of 1:1:1 (norepinephrine:Na+:Cl-) is energetically favorable, allowing NET to concentrate norepinephrine approximately 10,000-fold inside neurons relative to extracellular concentrations[@gu2006][@kaufmann2006].
Substrate Specificity
NET exhibits broad substrate specificity among monoamines:
| Substrate | Relative Affinity | Notes |
|-----------|-------------------|--------|
| Norepinephrine | High (Km ~0.1-0.5 μM) | Primary substrate |
| Epinephrine | Moderate | Less efficiently transported |
| Dopamine | Low | Can be transported |
| Amphetamine | High | Substrate-type inhibitor |
| Methylphenidate | High | Potent inhibitor |
This substrate profile has important pharmacological implications, as many psychostimulants (amphetamine, methylphenidate) exert their effects in part through NET inhibition and subsequent increases in extracellular norepinephrine[@barton2013].
Pharmacological Targets
NET is a major target for therapeutic drugs:
Tricyclic antidepressants: Desipramine, nortriptyline, imipramine
Selective norepinephrine reuptake inhibitors (SNRIs): Atomoxetine, reboxetine
Psychostimulants: Amphetamine, methylphenidate
Antihypertensives: Guanethidine, reserpine (historical)
Anorectants: Phentermine, sibutramine (historical)The development of selective NET inhibitors has been crucial for treating depression, ADHD, and narcolepsy, while also providing tools for understanding norepinephrine signaling in health and disease[@barton2013][@harrison2016].
Neurobiology
Brain Distribution
NET is expressed primarily in noradrenergic neurons of the central nervous system:
- Locus Coeruleus (LC): The primary source of central norepinephrine, with densely NET-positive neurons
- Lateral Tegmental Area (A1/A2): Secondary noradrenergic cell groups
- Bed Nucleus of the Stria Terminalis: Moderate NET expression
- Certain hypothalamic nuclei: NET expression in stress-related circuits
The locus coeruleus is the predominant norepinephrine-producing nucleus in the brain, projecting to virtually all brain regions including the cortex, hippocampus, thalamus, cerebellum, and spinal cord. NET expression on these projections ensures efficient reuptake of released norepinephrine, limiting the spatial spread of signaling and recycling neurotransmitter for reuse[@weinshenker2008][@mravec2011].
Role in Synaptic Transmission
NET performs several critical functions in noradrenergic synapses:
Signal termination: Rapidly removes norepinephrine from the synaptic cleft (half-life ~5-10 minutes)
Temporal precision: Limits the duration of norepinephrine signaling
Spatial containment: Restricts norepinephrine diffusion to the synapse
Neurotransmitter recycling: Recycled norepinephrine is repackaged into vesicles
Homeostatic regulation: Maintains steady-state neurotransmitter levelsThe density and activity of NET directly modulate the strength and duration of noradrenergic signaling, making it a critical determinant of catecholamine neurotransmission in normal and pathological states[@esler1976][@goldstein1995].
Clinical Significance
Parkinson's Disease
In [Parkinson's Disease](/diseases/parkinsons-disease), the norepinephrine system is profoundly affected, with degeneration of locus coeruleus neurons occurring early in disease pathogenesis, often before dopaminergic loss in the substantia nigra. NET alterations in PD include:
- Reduced NET binding: PET studies using 11C-MRB show decreased NET availability in PD brain[@sotak2005]
- Vulnerability of LC neurons: The locus coeruleus is particularly vulnerable to α-synuclein pathology
- Neuroprotective role of NE: Norepinephrine provides neuroprotection to dopaminergic neurons
- Non-motor symptoms: Noradrenergic dysfunction contributes to autonomic failure, depression, and cognitive impairment in PD
The relationship between NET and PD has led to interest in norepinephrine-enhancing therapies for PD symptoms, including norepinephrine reuptake inhibitors and norepinephrine agonists[@kish2008][@rommelfanger2007][@weinshenker2008].
Alzheimer's Disease
The locus coeruleus is also affected early in [Alzheimer's Disease](/diseases/alzheimers-disease), with noradrenergic dysfunction contributing to multiple aspects of AD pathology:
- Neuron loss: Progressive degeneration of locus coeruleus neurons in AD[@manaye2007]
- NE depletion: Reduced norepinephrine levels in AD brain tissue
- Neuroinflammation: NE modulates microglial activation; loss may increase inflammation
- Cognitive dysfunction: Noradrenergic signaling is critical for attention and memory
- Therapeutic potential: Enhancing norepinephrine signaling may improve cognition in AD
The LC degeneration in AD may precede the classic cholinergic and dopaminergic deficits, making noradrenergic restoration a potential early intervention strategy[@fuller2010][@szot2005][@german2012][@ch2012].
Major Depressive Disorder
NET dysfunction is strongly implicated in [major depressive disorder](/diseases/depression):
- NET binding alterations: Reduced NET density in depression (state vs. trait effects unclear)
- NET gene polymorphisms: Variants associated with antidepressant response
- Mechanism of antidepressants: Many antidepressants inhibit NET (TCAs) or increase NE signaling
- Biomarker potential: NET PET may predict treatment response
The effectiveness of norepinephrine-enhancing antidepressants (TCAs, SNRIs) validates NET as a therapeutic target in depression[@hauck2010][@lep2012][@harrison2016].
ADHD
NET variants contribute to [attention-deficit hyperactivity disorder](/diseases/adhd) risk:
- NET polymorphisms: Several variants associated with ADHD susceptibility
- Methylphenidate effects: NET inhibition is a key mechanism of ADHD treatment
- DAT-NET interactions: Dopamine and norepinephrine transporters interact functionally
- Dysregulation: Altered NET expression and function in ADHD brains
The noradrenergic system, through NET modulation, plays a central role in attention and executive function, making NET a critical target for ADHD therapeutics[@zanner2010][@rhee2011].
Orthostatic Intolerance
NET deficiency causes familial dysautonomia (or orthostatic intolerance), characterized by:
- Genetic causes: Mutations in SLC6A2 gene
- Clinical features: Orthostatic hypotension, tachycardia, syncope
- Pathophysiology: Impaired norepinephrine reuptake leads to reduced NE stores
- Treatment: Fludrocortisone, midodrine (α1 agonist)
Rare NET mutations demonstrate the critical role of this transporter in cardiovascular and autonomic regulation[@hauck2010].
Expression Pattern
Peripheral Expression
Outside the CNS, NET is expressed in:
- Sympathetic nerve terminals: Primary peripheral site
- Adrenal medulla: Some NET expression in chromaffin cells
- Platelets: Low levels (minor peripheral NE storage)
The peripheral noradrenergic system regulates:
- Blood pressure through vascular tone
- Heart rate and contractility
- Sweat gland function
- Gastrointestinal motility
CNS Expression Patterns
High expression regions include:
- Locus Coeruleus (highest density)
- Bed Nucleus of the Stria Terminalis
- Certain hypothalamic nuclei
- Dorsal raphe nucleus (non-monoaminergic cells)
Key Research Findings
1. Molecular Cloning
Byerly and colleagues first cloned NET from rat brain, demonstrating that the transporter shares structural features with other SLC6 family members. This work established the foundation for understanding NET structure and function at the molecular level[@byerly1989].
2. Structural Studies
Kaufmann and colleagues solved the first crystal structure of a neurotransmitter transporter (LeuT), providing insights into the mechanism of ion coupling and substrate transport applicable to NET. These structural studies revealed an unusual mechanism where Na+ ions participate directly in substrate binding rather than just providing energy for transport[@kaufmann2006].
3. NET in PD Vulnerability
Sotak and colleagues demonstrated decreased NET binding in the locus coeruleus of PD patients using PET imaging with 11C-MRB. This work established NET as a biomarker for noradrenergic degeneration in PD and potentially for disease progression[@sotak2005].
4. Therapeutic Implications
Rommelfanger and Weinshenker reviews established the "norepinephrine deficiency" hypothesis of PD, suggesting that enhancing norepinephrine signaling could provide neuroprotection and improve non-motor symptoms in PD patients[@rommelfanger2007][@weinshenker2008].
PET Imaging
NET availability can be assessed in vivo using PET ligands:
| Ligand | Use | Status |
|--------|-----|--------|
| 11C-MRB | NET binding | Research |
| 18F-Fluoroethyl-L-PET | NET imaging | Research |
| 123I-MIBG | Peripheral NET | Clinical |
PET imaging with NET ligands provides valuable information about noradrenergic neuron integrity in neurodegenerative diseases and may serve as a biomarker for disease progression and treatment response[@orourke2014].
Therapeutic Implications
Drug Development
Several strategies target NET for therapeutic benefit:
NET inhibitors: Atomoxetine, reboxetine for depression/ADHD
Norepinephrine agonists: Clonidine, guanfacine for hypertension
Combination approaches: DAT/NET inhibitors (serotonin-norepinephrine reuptake inhibitors)
Gene therapy: Potential for NET delivery in specific disordersBiomarker Potential
NET PET may serve as a biomarker for:
- Noradrenergic neuron integrity in AD and PD
- Treatment response to noradrenergic agents
- Disease progression in neurodegenerative disorders
Related Pages
- [Norepinephrine](/entities/norepinephrine)
- [Locus Coeruleus](/cell-types/locus-coeruleus-neurons)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Depression](/diseases/depression)
- [ADHD](/diseases/adhd)
- [Dopamine Transporter (DAT) Gene](/genes/slc6a3)
- [Serotonin Transporter (SERT) Gene](/genes/slc6a4)
External Links
- [NCBI Gene - SLC6A2](https://www.ncbi.nlm.nih.gov/gene/6530)
- [UniProt - SLC6A2](https://www.uniprot.org/uniprot/P23975)
- [Ensembl - SLC6A2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170270)
- [GeneCards - SLC6A2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC6A2)
- [HGNC - SLC6A2](https://www.genenames.org/data/hgnc_data.php?hgnc_id:11028)
Brain Atlas Resources
- [Allen Human Brain Atlas - SLC6A2](https://human.brain-map.org/microarray/search/show?search_term=SLC6A2)
- [Allen Cell Type Atlas](https://celltypes.brain-map.org/)
- [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/)
Pathway Diagram
The following diagram shows the key molecular relationships involving SLC6A2 — Norepinephrine Transporter discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)